CHICAGO, IL / ACCESSWIRE / December 1, 2023 / Cosmos Health Inc. (“Cosmos Well being” or the “Firm”) (NASDAQ:COSM), a diversified, vertically built-in international healthcare group engaged in revolutionary R&D, proprietor of proprietary pharmaceutical and nutraceutical manufacturers, producer and distributor of healthcare merchandise, and operator of a telehealth platform, introduced at the moment that it has filed a patent software with the European Patent Workplace (EPO) underneath reference code PCT/EP2023/083947 (submitting date December 1, 2023) for its CCX0722 weight problems and weight administration product.
This marks an essential milestone within the Firm’s dynamic and rising R&D pipeline, emphasizing its dedication to safeguarding mental property and fueling the expansion of its revolutionary healthcare options.
The patent software consists of knowledge derived from intensive scientific analysis and vital developments within the growth of CCX0722. By using novel amino acid-based cross-linkers, a collection of water-absorbent polymeric networks, often known as superabsorbent hydrogels (SAHs), has emerged as promising candidates for weight administration and weight problems. These SAHs obtain a swelling ratio of greater than 100 g/g and reveal considerably superior traits in comparison with present alternate options, as depicted within the graph under.
S.R. = Swelling Ratio
Determine: Comparative Outcomes for CCX Merchandise A and B Versus Present Hydrogel
Encouraging outcomes from these newly modified hydrogels affirm the Firm’s dedication to crafting novel merchandise with enhanced exercise, highlighting its expansive imaginative and prescient and dedication to exploring revolutionary pathways.
Because the Firm continues to advance its R&D program, it plans to file further patent purposes in an effort to replicate the substantial developments in product growth and assist safe a outstanding place within the biotechnology area.
Greg Siokas, Chief Govt Officer of Cosmos Well being, said: “Analysis and innovation are in our DNA. Through the years, we’ve assembled a world-class crew of scientists and established a top-tier R&D division. We’re thrilled with the progress in growing CCX0722 and sit up for shaping the way forward for weight administration options. These achievements replicate our crew’s steadfast dedication. We’re additionally desperate to proceed our pioneering and trailblazing journey within the pharmaceutical sector at a good quicker tempo with further thrilling R&D tasks within the pipeline. To this finish, as beforehand introduced, we stay devoted to remodeling our R&D division right into a separate, standalone, publicly listed firm, aiming to speed up our efforts in what we imagine to be a transformative catalyst for our shareholders.”
About Cosmos Well being Inc.
Cosmos Well being Inc. (Nasdaq:COSM), integrated in 2009 and headquartered in Chicago, Illinois, is a diversified, vertically built-in international healthcare group. The Firm owns a portfolio of proprietary pharmaceutical and nutraceutical manufacturers, together with Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. By means of its subsidiary Cana Laboratories S.A., licensed underneath European Good Manufacturing Practices (GMP) and licensed by the European Medicines Company, it manufactures prescription drugs, meals dietary supplements, cosmetics, biocides, and medical units throughout the European Union. Cosmos Well being additionally distributes a broad line of prescription drugs and parapharmaceuticals, together with branded generics and OTC medicines, to retail pharmacies and wholesale distributors by its subsidiaries in Greece and the UK. Moreover, the Firm has established R&D partnerships focusing on main well being issues equivalent to weight problems, diabetes, and most cancers, and focuses on the R&D of novel patented nutraceuticals, specialised root extracts, proprietary complicated generics, and revolutionary OTC merchandise. Cosmos Well being has additionally entered the telehealth area by the acquisition of ZipDoctor, Inc., primarily based in Texas, USA. With a worldwide distribution platform, the Firm is at present increasing all through Europe, Asia, and North America, and has workplaces and distribution facilities in Thessaloniki and Athens, Greece, and in Harlow, UK. Extra info is offered at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, and www.zipdoctor.co.
Except for the historic info contained on this information launch, the issues described herein, could include forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Change Act of 1934, as amended. Statements preceded by, adopted by, or that in any other case, embrace the phrases “believes,” “expects,” “anticipates,” “intends,” “tasks,” “estimates,” “plans” and related expressions or future or conditional verbs equivalent to “will,” “ought to,” “would,” “could” and “may”, are usually forward-looking in nature and never historic info, though not all forward-looking statements embrace the foregoing. These statements, contain unknown dangers and uncertainties that will individually or materially influence the issues mentioned, herein for quite a lot of causes which are outdoors the management of the Firm, together with, however not restricted to, the Firm’s means to lift adequate financing to implement its marketing strategy, the influence of the COVID-19 pandemic and the struggle in Ukraine, on the Firm’s enterprise, operations and the financial system basically, and the Firm’s means to efficiently develop and commercialize its proprietary merchandise and applied sciences. Readers are cautioned to not place undue reliance on these forward- trying statements, as precise outcomes may differ materially from these described within the forward-looking statements contained herein. Readers are urged to learn the chance components set forth within the Firm’s filings with the SEC, which can be found on the SEC’s web site (www.sec.gov). The Firm disclaims any intention or obligation to replace, or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.
Investor Relations Contact:
+44 207 0971 653
SOURCE: Cosmos Well being Inc.
View supply model on accesswire.com: